SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 201.28-2.1%Nov 13 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: shasta23 who wrote (18816)4/7/1998 2:44:00 PM
From: Peter Singleton  Read Replies (1) of 32384
 
fyi, CTCL competition

SuperGen <SUPG.O> secures orphan drug designation

SAN RAMON, Calif., April 6 (Reuters) - SuperGen Inc said Monday it received Orphan Drug Designation from the U.S. Food and Drug Administration for Nipent in cutaneous T-cell lymphoma (CTCL).

SuperGen said in a statement that it plans to submit a Supplemental New Drug Application to market Nipent to treat CTCL by the end of 1998.

SuperGen already markets Nipent in the U.S. for hairy cell leukemia, and has received Orphan Drug Designation in the area of chronic lymphocytic leukemia. Orphan drugs receive a seven-year period of exclusivity from the date they are cleared by the FDA.

The company said that data from several studies show Nipent used as a single chemotherapeutic agent has produced clinically significant response rates in patients with CTCL.

"This is the first step in extending Nipent beyond its initial indication and into new markets that could eventually total in excess of $200 million," Chief Executive Dr. Joseph Rubinfeld said.

"There are significantly more patients with CTCL than there are with hairy cell leukemia," Rubinfeld said. "Under allowance by the FDA, we will actively distribute appropriate independent clinical information about Nipent and CTCL to physicians."

14:31 04-06-98
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext